셀트리온

068270KOSPI

58.0 / 100

Reference Date: 2026-10-23

Financial Score17.5 / 40

News Sentiment12.5 / 25

Momentum14.0 / 20

Disclosure14.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Rose 9.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Celltrion is a global biotech company specializing in developing and commercializing biopharmaceuticals for autoimmune diseases and oncology, with 11 globally approved biosimilar products, including its first biosimilar, Remsima (CT-P13). It has expanded its global presence through strong market dominance in Europe and the U.S., and secured FDA approval for its subcutaneous infliximab formulation in 2023, aiming for 41.625 trillion KRW in sales by 2025.

Number of Employees

3,153people

Average Salary

108.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

41.45Industry Average 15.000.0Point

2.8x industry avg (risky)

PBR

2.59Industry Average 1.200.0Point

2.2x industry avg (risky)

ROE

5.91Industry Average 8.002.5Point

Below industry avg

Debt Ratio

3.05Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲40.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲56.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 4.5% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (37%)

Current 193,500Won52-week high 248,50052-week low 160,500

1-month return5.0Point

1m +9.08% (rising)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 2Neutral 3Negative 0

Neutral투자판단관련주요경영사항 (반감기 연장 기술이 적용된 장기 지속형 항APRIL 항체 Licensein 계약 체결)2026-10-22
Positive자기주식취득결과보고서2026-10-20
Neutral투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 한국 임상 3상 시험계획 승인)2026-10-14
Neutral연결재무제표기준영업(잠정)실적(공정공시)2026-10-12
Positive주요사항보고서(자기주식취득결정)2026-09-29